Humana to release Q2 2026 results on July 29, 2026

1 min read | Published on 23 Jun 2026, 02:34 AM |Updated on 23 Jun 2026, 02:34 AM

Reviewed by

Anirudha BScanX News Team

Key Highlights

Humana Inc. will announce its Q2 2026 financial results on July 29, 2026, followed by a live Q&A session. The earnings release will include non-GAAP financial measures with a reconciliation to GAAP. Participants can register in advance for the call, and a webcast archive will be available later.

*this image is generated using AI for illustrative purposes only.

Humana Inc. will release its financial results for the second quarter of 2026 (2Q26) on July 29, 2026, at 6:00 a.m. Eastern time. The company will also provide prepared management remarks in PDF format. A live question-and-answer session is scheduled for 8:00 a.m. Eastern time the same day to discuss the quarterly results and earnings guidance for 2026.

The 2Q26 earnings call webcast will be accessible via Humana’s Investor Relations page at https://humana.gcs-web.com/ . Participants wishing to ask questions during the session must register in advance at https://register-conf.media-server.com/register/BI18085d824058461aa3c6b8b2af27cb40 . Upon registration, telephone participants will receive a confirmation email with dial-in details and a unique registrant ID.

Humana advises participants to sign in or dial in at least 15 minutes before the call. For those unable to attend the live event, a virtual presentation archive will be available approximately two hours after the webcast in the Historical Webcasts and Presentations section of the Investor Relations page.

The company’s 2Q26 earnings news release will include financial measures not in accordance with Generally Accepted Accounting Principles (GAAP). A reconciliation of these non-GAAP measures to GAAP results, along with management’s rationale for their inclusion, will be provided in the release and available on the Investor Relations page at www.humana.com on July 29, 2026.

Key Event Details

Event	Date	Time (Eastern)
Financial Results Release	July 29, 2026	6:00 a.m.
Live Q&A Session	July 29, 2026	8:00 a.m.
Webcast Archive Availability	July 29, 2026	~2 hours post-webcast

Humana is a leading U.S. healthcare company providing insurance services through Humana and healthcare services through CenterWell. The company serves millions of individuals, including those with Medicare and Medicaid, military personnel, and communities at large.

How might the 2Q26 earnings results influence Humana's strategic priorities for the remainder of 2026?

What potential market reactions could investors expect following the release of non-GAAP financial measures?

Could the earnings guidance for 2026 signal shifts in Humana's approach to Medicare and Medicaid services?

KSF continues investigation into Humana Inc. officers and directors

1 min read | Published on 15 Jun 2026, 11:41 PM |Updated on 15 Jun 2026, 11:41 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Kahn Swick & Foti LLC is continuing its investigation into Humana Inc.'s officers and directors regarding potential breaches of fiduciary duties. The inquiry follows Humana's disclosure of increased benefits expense ratios and a significant downward revision of its 2024 earnings guidance. A related securities class action lawsuit has survived a motion to dismiss, allowing the case to proceed.

*this image is generated using AI for illustrative purposes only.

Kahn Swick & Foti LLC continues its investigation into the officers and directors of Humana Inc., focusing on whether they breached their fiduciary duties to shareholders or violated state or federal laws. The law firm's scrutiny follows a series of financial disclosures in early 2024 that revealed rising medical costs and missed earnings targets, leading to a securities class action lawsuit that has been allowed to proceed.

On January 18, 2024, Humana announced its financial results for the fourth quarter and full year 2023. The company reported that its benefits expense ratio increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023. This resulted in 2023 adjusted earnings per share (EPS) of $26.09, which was more than $2 per share less than the company had predicted in November 2023.

Subsequently, on January 25, 2024, Humana disclosed a loss for the fourth quarter of 2023. The company indicated that higher medical costs would persist throughout 2024, projecting adjusted EPS of only $16 per share for the year. This forecast represented a $10 per share decrease from 2023 and fell well below analysts' expectations of $29 per share.

Following these disclosures, Humana and certain executives were named in a securities class action lawsuit. The complaint alleges that the defendants failed to disclose material information during the Class Period, violating federal securities laws. Recently, the court presiding over the case denied the company's motion to dismiss in part, allowing the lawsuit to move forward.

Key Financial Disclosures

Metric	Q4 2023	Full Year 2023	2024 Guidance
Benefits Expense Ratio	~91.4%	~88%	N/A
Adjusted EPS	N/A	$26.09	$16.00

Kahn Swick & Foti LLC, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a boutique securities litigation firm. The firm is seeking information from long-term holders of Humana shares to assist in its investigation regarding potential corporate malfeasance.

How will the ongoing litigation and investigation impact Humana's strategic decisions and executive leadership in 2024?

What measures is Humana implementing to address the rising medical costs and improve its benefits expense ratio?

Could the projected decline in EPS lead to changes in Humana's dividend policy or share buyback programs?